MHRA-100516-PIP01-22

Key Facts

Active Substance
Active Substance:
  • Toripalimab
Invented Name
  • Not available at present
  • TUOYI
PIP Number MHRA-100516-PIP01-22
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Concentrate for solution for infusion
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Malignant neoplasms (except CNS, haematopoietic and lymphoid tissue and melanoma).
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Toripalimab.pdf
Published Date 03/11/2022